Lastly, there is an ongoing phase 1 clinical trial of anti-CD19 CAR T-cells combined with fludarabine and cyclophosphamide for patients with relapsing or progressive MS or refractory MG (NCT06220201) (67). The gene discussed is CD19; the disease is myasthenia gravis.